adult CHD were retrospectively included. Adverse events were assessed using the Bergersen classification. Results 174 stents were implanted during 132 procedures in 127 patients by 6 main operators in 9 centers. Patients were aged 15.7 ± 15.1 years old (min 5 day-old -max 70 years old). Sixteen types of procedures were identified. Main indications were transcatheter pulmonary valve replacement (29 patients, 23.0%), pulmonary artery branches angioplasty (34 patients, 27.0%), aortic (re)coarctation stenting (37 patients, 29.4%) and ductus arteriosus stenting (11 patients, 8.7%). 18 patients (14.3%) were under one y.o and 35 (27.8%) were over 18 y.o. Main pathologies were tetralogy of Fallot and variants (ACC-CHD 8.3, n = 45, 35.7%), and aortic coarctation (ACC-CHD 9.2, n = 36, 28.6%). More than 1 stent was implanted in 32 procedures (24.4%, max. 5 stents). Main stents implanted were the CP stent (33.0%), EV3 LD max (22.0%), Valeo (16.2%) and valved stents (15.0%). 98.5% procedures were considered as successful. Serious adverse events were observed in 12.9%. After multivariate adjustment, only procedure type was related to the risk of total adverse events (OR: 3.0, 95%CI 1.1-7.9) but not to stent related adverse events. Age, weight, center, operator, type of stents, stent diameter, genetic disorder and type of CHD were not significantly related to the risk of adverse events. Conclusion Stents are used in various CHD catheterization procedures, from infancy to adult age. Adverse events rate is significant and seems related to the type of procedure. Five pts had a 3rd surgery (3 MVR, 3 valvuloplasty), 2 had a 4th surgery (redo MVR). There were 6 deaths (overall mortality 12%): 2 after first surgery (1 valvuloplasty, 1 MVR, respectively 8 and 14 days postop), 4 after the second surgery (24 days and 3.5 mo after valvuloplasty, 30 days and 31 yrs after MVR). Risk factors for postoperative death were: presence of supravalvular lesions (left superior vena cava in the coronary sinus and/or supramitral ring, P < 0.04), surgery for supravalvular lesions (P < 0.04), longer cardiac bypass time (P < 0.03) and longer ICU stay duration (P < 0.01). Risk factors for reoperation were younger age (P = 0.008) and low weight (P < 0.04) at first surgery. Conclusion Valvuloplasty as first-choice surgery for CMVS carries an acceptable initial mortality but a relatively high rate of reoperations (29%). Iterative plasty is possible but mortality is higher (18%).
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